Canada - English - Health Canada

h w naylor co inc. - scarlet red; oxyquinoline; camphor; phenol - aerosol - 0.19%; 0.5%; 0.65%; 3.25% - scarlet red 0.19%; oxyquinoline 0.5%; camphor 0.65%; phenol 3.25% - cattle; horses; dogs

Canada - English - Health Canada

wyeth-ayerst canada inc. - benzocaine; benzethonium chloride; menthol; oxyquinoline benzoate; methylparaben - aerosol - 4.5%; 0.1%; 0.5%; 1.2%; 2% - benzocaine 4.5%; benzethonium chloride 0.1%; menthol 0.5%; oxyquinoline benzoate 1.2%; methylparaben 2% - miscellaneous local anti-infectives

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - risperidone 2mg;   - film coated tablet - 2 mg - active: risperidone 2mg   excipient: colloidal silicon dioxide hypromellose iron oxide red lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opadry white y-1-7000 quinoline yellow

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - risperidone 3mg;   - film coated tablet - 3 mg - active: risperidone 3mg   excipient: colloidal silicon dioxide hypromellose lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opadry white y-1-7000 quinoline yellow

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - risperidone 4mg;   - film coated tablet - 4 mg - active: risperidone 4mg   excipient: colloidal silicon dioxide hypromellose indigo carmine lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opadry white y-1-7000 quinoline yellow

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - risperidone 6mg;   - film coated tablet - 6 mg - active: risperidone 6mg   excipient: colloidal silicon dioxide hypromellose lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opadry white y-1-7000 quinoline yellow

New Zealand - English - Medsafe (Medicines Safety Authority)

jntl consumer health (new zealand) limited - nicotine polacrilex 20mg equivalent to to 4 mg nicotine;  ;   - chewing gum - 4 mg - active: nicotine polacrilex 20mg equivalent to to 4 mg nicotine     excipient: cafosa 257 classic flavour for smoker 84.6422 glycerol menthol flavour zd49284 quinoline yellow sodium carbonate sorbitol - for the treatment of tobacco dependence by relieving nicotine craving and withdrawal symptoms thus: facilitating smoking cessation in smokers motivated to quit. helping smokers to temporarily abstain from smoking. facilitating smoking reduction in smokers unable or unwilling to quit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefalexin monohydrate, quantity: 500 mg - capsule, hard - excipient ingredients: dimeticone 350; magnesium stearate; patent blue v; quinoline yellow; titanium dioxide; gelatin; microcrystalline cellulose; carmellose sodium; purified water; shellac; industrial methylated spirit; iron oxide black; 2-ethoxyethanol; dimeticone 1000; lecithin - indications as at 24 february 2004: keflex is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. keflex is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of keflex in the subsequent prevention of rheumatic fever are not available at present.) bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only) otitis media due to s. pneumoniae, staphylococci; skin and soft tissue infections caused by staphlococci anr/or streptococci; genitourinary tract infections, including acute prostatic caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of keflex in the treatment of bacterial infections of the brain and spinal column has not been established and keflex is not indicated in these conditions. note: appropriate culture and susceptibility test should be initiated prior to and during therapy to determine susceptibility of the causative organism to keflex. renal function studies should be performed when indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefalexin monohydrate, quantity: 250 mg - capsule, hard - excipient ingredients: dimeticone 350; magnesium stearate; patent blue v; quinoline yellow; titanium dioxide; gelatin; microcrystalline cellulose; carmellose sodium; purified water; shellac; industrial methylated spirit; iron oxide black; 2-ethoxyethanol; dimeticone 1000; lecithin - indications as at 24 february 2004: keflex is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. keflex is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of keflex in the subsequent prevention of rheumatic fever are not available at present.) bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only) otitis media due to s. pneumoniae, staphylococci; skin and soft tissue infections caused by staphlococci anr/or streptococci; genitourinary tract infections, including acute prostatic caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of keflex in the treatment of bacterial infections of the brain and spinal column has not been established and keflex is not indicated in these conditions. note: appropriate culture and susceptibility test should be initiated prior to and during therapy to determine susceptibility of the causative organism to keflex. renal function studies should be performed when indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - methyldopa sesquihydrate, quantity: 283 mg (equivalent: methyldopa, qty 250 mg) - tablet, film coated - excipient ingredients: guar gum; titanium dioxide; purified talc; sodium calcium edetate; iron oxide red; citric acid; quinoline yellow aluminium lake; hypromellose; ethylcellulose; propylene glycol; carnauba wax; magnesium stearate; powdered cellulose; colloidal anhydrous silica; citric acid monohydrate - hypertension (mild, moderate to severe).